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Development and Progression of Diabetic Retinopathy
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OBJECTIVE—Mitochondrial superoxide levels are elevated in
the retina in diabetes, and manganese superoxide dismutase
overexpression prevents the development of retinopathy. Super-
oxide inhibits glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), which activates major pathways implicated in diabetic
complications, including advanced glycation end products
(AGEs), protein kinase C, and hexosamine pathway. Our aim is
to investigate the role of GAPDH in the development and progres-
sion of diabetic retinopathy and to elucidate the mechanism.
RESEARCH DESIGN AND METHODS—Rats with streptozo-
tocin-induced diabetes were in a state of poor control (GHb
11%) for 12 months, good control (GHb 7) soon after induc-
tion of diabetes, or poor control for 6 months with 6 months’
good control. Retinal GAPDH, its ribosylation and nitration,
AGEs, and PKC activation were determined and correlated with
microvascular histopathology.
RESULTS—In rats with poor control, retinal GAPDH activity
and expressions were subnormal with increased ribosylation and
nitration (25–30%). GAPDH activity was subnormal in both
cytosol and nuclear fractions, but its protein expression and
nitration were signiﬁcantly elevated in nuclear fraction. Reinsti-
tution of good control failed to protect inactivation of GAPDH, its
covalent modiﬁcation, and translocation to the nucleus. PKC,
AGEs, and hexosamine pathways remained activated, and micro-
vascular histopathology was unchanged. However, GAPDH and
its translocation in good control rats were similar to those in
normal rats.
CONCLUSIONS—GAPDH plays a signiﬁcant role in the devel-
opment of diabetic retinopathy and its progression after cessa-
tion of hyperglycemia. Thus, therapies targeted toward
preventing its inhibition may inhibit development of diabetic
retinopathy and arrest its progression. Diabetes 58:227–234,
2009
R
etinopathy is a multifactorial sight-threatening
complication of diabetes. It is a progressive
disease associated with chronic hyperglycemia
(1). Although many glucose-induced retinal met-
abolic abnormalities are postulated to contribute to its
development, the exact mechanism remains elusive (2–5).
We have shown that in diabetes, retinal mitochondria
experience increased oxidative damage and the mitochon-
drial enzyme that scavenges superoxide (manganese
superoxide dismutase [MnSOD]) prevents vascular his-
topathology that is characteristic of diabetic retinopathy
(6–8). Increased mitochondrial superoxide production
inactivates glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) in vascular endothelial cells, and inhibition of
GAPDH is postulated to activate some of the key pathways
that are associated with the development of diabetes
complications, including increased formation of advanced
glycation end products (AGEs) and activation of protein
kinase C (PKC) and hexosamine pathway (9,10).
GAPDH is a glycolytic enzyme that catalyzes the con-
version of glyceraldehyde-3-phosphate to 1,3-bis-phospho-
glycerate. Recent studies have shown that GAPDH is a
protein with multiple cytoplasmic, membrane, and nuclear
functions and is a major intracellular messenger mediating
apoptosis of cells (11,12). GAPDH translocation to the
nucleus is considered an important step in glucose-in-
duced apoptosis of retinal Muller cells (13). The mecha-
nism that initiates its translocation is not well understood;
covalent modiﬁcation by nitration/ribosylation is consid-
ered a likely possibility (14–16). How GAPDH contributes
to the pathogenesis of diabetic retinopathy remains to be
established.
Good glycemic control attenuates the development/
progression of retinopathy in diabetic patients, but its
effects on the progression of retinopathy are not immedi-
ate, and it takes years for retinopathy to halt progression
after the reestablishment of good control. The imprinted
effects of prior glycemic control either produce the long-
lasting beneﬁts of good control or resist the arrest of
progression of diabetic retinopathy after reinstitution of
good control. Reinstitution of good control after a pro-
found period of poor glycemic control does not immedi-
ately beneﬁt the progression of retinopathy. This suggests
a “metabolic memory” phenomenon (17–20). Metabolic
memory phenomenon is observed also in animal models of
diabetic retinopathy (21–26); the formation of acellular
capillaries, characteristic of early signs of diabetic retinop-
athy, does not stop for at least 6 months when good
control is initiated 6 months after induction of diabetes in
rats, and nitrotyrosine levels and oxidative stress remain
elevated (24,26). These abnormalities are, however, par-
tially inhibited if the duration of poor control is reduced to
2 months, suggesting the role of oxidative stress in the
metabolic memory phenomenon (24). The role of GAPDH
in metabolic imprinting remains to be elucidated.
In the present study, we investigated how GAPDH
inhibition contributes to the development of retinopathy in
diabetes and the mechanism(s) that could result in its
inactivation. We have also explored the role of GAPDH in
the metabolic memory phenomenon in diabetic rats by
maintaining them in a state of poor control before initia-
tion of a state of good control.
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Animals and glycemia. Lewis rats (male, 200 g) were randomly assigned to
normal or diabetic groups. Diabetes was induced with streptozotocin (55
mg/kg body wt), and rats were divided at random among three groups
according to intended degree of glycemic control. Rats in group 1 remained in
poor control for 12 months; in group 2, rats were in poor control for 6 months
followed by good control for 6 additional months (poor control–good con-
trol); and in group 3, rats were subjected to good control soon after induction
of diabetes. Some of the same rats had been used by us in our previous studies
(26,27).
The degree of glycemia was achieved by adjusting the dose and frequency
of insulin (NPH) administration. The rats in the poor-control group received a
single injection of insulin (1–2 units) four to ﬁve times a week to prevent
ketosis and weight loss, and the rats in good control group received insulin
twice daily (7–8 units total) to maintain their blood glucose levels below 150
mg/dl and a steady gain in body weight (24,26). The entire rat colony was
housed in metabolism cages: 24-h urine samples were measured daily and
tested for glycosuria. Blood glucose was measured once a week using Elite
Glucometer (Bayer, Tarrytown, NY), and GHb was measured every 2 months.
The entire rat colony received a powdered diet (Purina 5001; TestDiet,
Richmond, IN); their food consumption was measured once every week, and
body weights were measured two to three times every week. These experi-
ments conformed to the ARVO Resolution on Treatment of Animals in
Research and to the speciﬁc institutional guidelines. The experiment was
terminated 12 months after initiation of diabetes, and the animals were killed
by an overdose of pentobarbital. Eyes were enucleated immediately; one eye
was ﬁxed in 10% buffered formalin, and from the other eye, the retina was
immediately isolated by gently separating sensory retina from choroid using a
microspatula.
Preparation of subcellular fractions. Retina was gently homogenized in a
glass homogenizer in 50 mmol/l glycyl glycine buffer (pH 7.0) containing 10
mmol/l EDTA, 100 mmol/l sodium ﬂuoride, 0.5 mmol/l dithiolthreitol, and
protease inhibitors. The homogenate was centrifuged at 750g for 5 min, and
the supernatant was centrifuged at 5,000g for 15 min. The nuclear pellet was
resuspended in 50 mmol/l HEPES buffer (pH 7.5) containing 1% Triton X-100,
150 mmol/l sodium chloride, 1 mmol/l EDTA, and protease inhibitors. The
supernatant was further centrifuged at 105,000g for 90 min to separate the
cytosolic fraction (13,28). The purity of the fractions was determined by
measuring the expressions of Histone 2-B (nuclear marker) and lactate
dehydrogenase (LDH; cytosolic marker).
GAPDH enzyme activity. The enzyme activity was measured spectrophoto-
metrically in a ﬁnal assay volume of 100 l containing 50 mmol/l triethanol-
amine buffer (pH 7.6), 50 mmol/l arsenate, 2.4 mmol/l glutathione, 250 mol/l
NAD, and cytosolic/nuclear protein (0–10 g protein). The assay mixture was
preincubated for 5 min at 37°C, and the reaction was initiated by 100 g/ml
glyceraldehyde-3-phosphate. Increase in NADH production was monitored at
340 nm. GAPDH activity was expressed as difference in absorbance in the
presence/absence of glyceraldehyde-3-phosphate (28).
Quantitative real-time PCR. RNA was isolated from the retina using TRIzol
reagent, and 1 g RNA was converted to single-stranded cDNA and quantiﬁed
spectrophotometrically. Gene expression was measured using 90- to 300-ng
cDNA templates in 96-well plates in ABI-7500 sequence detection system
(29,30). Each sample was analyzed in triplicate, and the data were normalized
to 2-microglobulin (B2M) expression in each sample. GenBank accession
numbers for the ABI TaqMan assays for GAPDH and B2M used were
NM_017008.3 and NM_012512.1, respectively. The fold change in gene expres-
sion relative to normal was calculated using the delta delta cycles to threshold
(ddCT) method.
Protein expression. Protein (15–30 g) was separated by SDS-PAGE on a
4–16% gradient gel and blotted to nitrocellulose membrane. The membranes
were blocked in 5% nonfat milk, incubated with the target primary antibody,
washed, and followed by incubation with appropriate horseradish peroxi-
dase–coupled secondary antibody. The target proteins were enhanced by ECL
reagent and determined by autoradiography. The membranes then were
stripped and reprobed with -actin (Sigma-Aldrich, St. Louis, MO). The band
intensity was quantiﬁed using Un-Scan-It Gel digitizing software (Silk Scien-
tiﬁc, Orem, UT), and protein expression levels were calculated relative to
-actin in the same sample. Activity of poly(ADP-ribose) polymerase (PARP)
was determined by measuring poly(ADP-ribosyl)ation of retinal proteins by
separating them on SDS-PAGE gel.
Ribosylation and nitration of GAPDH. Covalent modiﬁcation of GAPDH
was determined by ﬁrst immunoprecipitating protein (75–100 g) with poly-
clonal anti-GAPDH antibody. Protein A/G plus agarose beads were used to
collect GAPDH complexed with the antibody and analyzed by Western blot
technique using monoclonal antibodies against poly(ADP-ribose) (PAR; Alexis
Biochemicals, San Diego, CA) and nitrotyrosine (Upstate Biotechnology, Lake
Placid, NY). To normalize for equal loading in each lane, the membranes were
reprobed for GAPDH.
Quantiﬁcation of GAPDH-mediated pathways. Because inhibition of
GAPDH activates major pathways that are implicated in the development of
diabetes complications, we investigated the effect of reversal of hyperglyce-
mia on AGEs, PKC, and hexosamine pathways in the retina from the same set
of animals used for GAPDH. Total AGEs formation was determined by
Western blot using anti-AGE antibody (Wako Chemicals, Richmond, VA). PKC
activation was determined by quantifying the expression of PKC II, the
isoform that is activated in diabetes, as we previously described (23).
Because addition of single O-linked ß-N-acetylglucosamine (O-GlcNAc)
monosaccharides to serine or threonine residues on proteins is one of the
processes coupled to the hexosamine pathway, we assessed hexosamine
pathway by quantifying O-linked N-acetylglucosamine–modiﬁed proteins in
the retina by Western blot using monoclonal antibody against O-GlcNAc
(Covance, Princeton, NJ). BSA was used as a blocking medium (30).
Isolation of retinal microvessels and quantiﬁcation of acellular
capillaries. Microvessels were prepared from formalin-ﬁxed eyes by trypsin
digestion. The retina was isolated, rinsed in water overnight, and incubated
with 3% crude trypsin containing 0.2 mmol/l sodium ﬂuoride for 90 min at
37°C. Nonvascular cells were removed by gentle brushing, and the isolated
vasculature was dried onto a microscope slide. The slides were stained with
hematoxylin and periodic acid Schiff. The number of acellular capillaries
(representing basement membrane tubes lacking cell nuclei) was counted in
a masked manner in multiple midretinal ﬁelds with one ﬁeld adjacent to each
of the ﬁve to seven retinal arterioles radiating out from the optic disc and
expressed as per square millimeter of retinal area examined (5,8,26).
Results are presented as means  SD and analyzed statistically using the
nonparametric Kruskal-Wallis followed by Mann-Whitney U test for multiple
group comparison. Similar conclusions were achieved by using ANOVA with
Fisher or Tukey tests.
RESULTS
Severity of hyperglycemia. Hyperglycemia, as reported
previously (26), was severe in the rats in the poor-control
group; GHb values were 11% throughout the entire
duration of the experiment (12 months). The rats in the
good-control group maintained their GHb values, which
were similar to those in normal rats. In the poor control–
good control group, GHb values before initiation of good
control were not different from the poor-control group
(GHb 11%) but became similar to those in the normal
group after initiation of good control (GHb 7%) (Table
1). Average body weight and 24-h urine volumes were
similar in good-control rats and normal rats.
Effect of diabetes on retinal GAPDH. Twelve months
of poor control had a marginal but statistically signiﬁcant
effect on the expression of GAPDH in the retina; protein
expression was decreased by 15–20% (Fig. 1) and gene
expression by 20% (Fig. 2) in diabetic rats.
Effect of diabetes on activation of retinal PARP.
As shown in Fig. 3A, 12 months of poor control signiﬁ-
cantly increased poly(ADP-ribosyl)ation of retinal proteins
TABLE 1
Degree of glycemia in rats assigned to different states of glycemic
control
n
Duration
(months)
Body wt
(g) GHb (%)
Urine volume
(ml/24 h)
Normal 9 12 421  35 6.7  0.8 13  6
PC 13 12 289  37 12.7  1.7 112  39
GC 7 12 454  41 6.9  1.1 26  10
PC 11 6 272  27 13.1  1.6 135  19
22 2 2 2
GC 6 409  26 7.1  0.9 19  11
Data are means  SD. The rats were weighed two times every week,
and their food consumption was measured once every week. Body
weight is the mean value during the entire duration of the intended
metabolic control.
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in PARP activity. We did not, however, identify these
ribosylated proteins (other than GAPDH, please see be-
low), and that is beyond the focus of this study.
Subcellular translocation of GAPDH and its covalent
modiﬁcation. Because retinal cell apoptosis precedes the
development of diabetic retinopathy (31,32), we investi-
gated the effect of diabetes on subcellular translocation of
GAPDH in the retina. In normal rat retina, the protein
expression of GAPDH was 35% higher in the cytosolic
fraction compared with the nuclear fraction, but 12
months of poor control in rats resulted in reduction in its
expression in the cytosol fraction, with a concomitant
increase in the nuclear fraction (Fig. 4). The ratio of
GAPDH expression in cytosolic and nuclear fraction was
almost 4:1 in normal rat retina and decreased to 1.2:1 in
diabetic rat retina. In the same diabetic rats, despite
increased expression of GAPDH, the glycolytic activity
was decreased by 70% in the nuclear fraction (Fig. 5A).
The good-control group had expressions similar to those
of the normal control rats (data not shown).
Ribosylation and nitration have been shown to inhibit
GAPDH activity (15,33). We determined the levels of its
ribosylation and nitration of retinal GAPDH. Twelve
months of poor control resulted in an 25% increase in
ribosylation of GAPDH (Fig. 3B) and a 30% increase in
nitration compared with the normal rat retina (Fig. 3). The
rats in the good-control group had expressions similar to
those of the normal-control rats (data not shown). The
ratio of nitrated GAPDH was 2.5:1 in normal rat retina and
increased to almost 1:1 in the poor-control group. How-
ever, in the nuclear fraction, nitrated GAPDH was about
twofold higher in poor-control rats compared with normal
rats (Fig. 5B), strongly suggesting that the enzyme in
nuclear fraction is mainly in its covalently modiﬁed and
inactivated form.
Effect of reversal of hyperglycemia on GAPDH. When
diabetic rats were allowed to remain in poor control for 6
months before institution of good control, the protein and
gene expressions of retinal GAPDH remained subnormal,
and PARP remained activated; values obtained in poor-
control and poor control–good control groups were not
different from each other (Figs. 1, 2, and 3A). In addition,
both ribosylation and nitration of GAPDH were also not
different in the retina from the poor-control group and
poor control–good control group, suggesting that 6
months of good control had no beneﬁcial effect on the
covalent modiﬁcation of the enzyme (Fig. 3B and C). The
expression and activity of GAPDH in nuclear fraction of
retina from the poor control–good control group were
signiﬁcantly different from those in normal rats, and the
enzyme remained nitrated (Figs. 4 and 5). However, these
values were similar to those obtained from the poor-
control group, suggesting that 6 months of good control
did not prevent the enzyme from translocating to the
nucleus and thus failed to protect the retina from apopto-
sis. But when the rats were maintained in good control
soon after induction of diabetes (good-control group),
GAPDH gene expression was similar to that obtained
from normal rat retina (Fig. 2).
Effect of reversal of hyperglycemia on GAPDH-
mediated pathways. As shown in Fig. 6A, multiple pro-
tein bands with increased AGEs were observed in the
retina from rats in the poor-control group compared with
those from normal rats, and protein staining from the rats
in the poor control–good control group was similar to
those obtained from the rats in the poor-control group.
We, however, did not identify the retinal proteins that had
increased AGEs. In the same retina samples, reversal of
hyperglycemia had no effect on increased PKCII (Fig.
6B); the enzyme expression remained signiﬁcantly ele-
vated in both the poor-control and the poor control–good
control groups compared with that in the normal group of
rats (P  0.05). Similarly, 6 months of good control did not
produce any reduction in O-GlcNAcylation of retinal pro-
teins (data not shown), conﬁrming that reversal of hyper-
glycemia had no beneﬁcial effect on GAPDH-mediated
downstream and upstream signaling pathways.
Effect of reversal of hyperglycemia on the retinal
histopathology. Poor glycemic control in rats for 12
months increased the number of acellular capillaries in the
FIG. 1. Protein expression of GAPDH in diabetes and effect of reversal
of glycemic control. GAPDH expression was determined in the retinal
homogenate by Western blot technique using rabbit polyclonal GAPDH
antibody. Equal loading of the sample in each lane was ensured by
determining the expression of -actin. The Western blots shown here
are representative of at least ﬁve different rats in each group, and the
bars represent the means  SD of the adjusted band intensities
obtained from those rats.
FIG. 2. Gene expression of GAPDH in the retina and effect of reinsti-
tution of good glycemic control. Retinal gene expression was measured
with quantitative real-time PCR, and the values were normalized to the
expression of the housekeeping gene B2M in the same sample. The
value obtained from the retina of age-matched normal rats is consid-
ered to be 100%. Data represent the means  SD from 8–10 rats in
each of the four groups. *P < 0.05 compared with normal; #P > 0.05
compared with poor control.
M. KANWAR AND R.A. KOWLURU
DIABETES, VOL. 58, JANUARY 2009 229retinal vasculature (Fig. 7) by about fourfold compared
with that in normal rats. The 6 months of good con-
trol that followed 6 months of poor control failed to
provide any protection; the number of acellular capillaries
was similar in poor-control and poor control–good con-
trol rats (average number of acellular capillaries per
millimeter squared of retina in rats in the normal, poor-
control, and poor control–good control groups: 1.5, 6.1,
and 6.8, respectively).
DISCUSSION
GAPDH, a classic glycolytic enzyme, is implicated in
diverse cytoplasmic, membrane, and nuclear activities and
has been shown to play a signiﬁcant role in cell death (12),
and its inhibition is considered to activate major pathways
of endothelial cell damage, including activation of PKC,
hexosamine pathway ﬂux, and AGE formation (9,10).
Here, we show that diabetes inhibits GAPDH activity in
the retina, and its expression becomes subnormal. The
enzyme is translocated from cytosol to the nucleus, and
GAPDH-mediated downstream and upstream signaling
pathways (AGEs, PKC, and the hexosamine pathway) are
activated. Our data suggest that the enzyme translocated
to the nuclear fraction is covalently modiﬁed. Further-
more, we provide exciting data demonstrating that reinsti-
tution of good control after 6 months of poor control does
not produce any beneﬁcial effects on the inactivation of
retinal GAPDH. The enzyme remains inactive with its
expression elevated in the nucleus, suggesting that inhibi-
tion of GAPDH and its subcellular translocation resist
reversal after reinstitution of good control. Reinstitution
of good control also fails to provide any beneﬁt to the
covalent modiﬁcation; the elevated levels of both ribosy-
lation and nitration are sustained for at least 6 months
after reversal of poor control. In the same animals the
signaling pathways that are in direct control of GAPDH
remain activated in the retina, and the number of acellular
capillaries remain elevated after reestablishment of good
control. These novel and exciting observations strongly
suggest a role for GAPDH in the development and progres-
sion of diabetic retinopathy.
Although others have reported decreased retinal
GAPDH activity at 3 months of diabetes duration in rats
(34), ours is the ﬁrst report showing that the enzyme
remains inhibited at duration of diabetes in rats when
signs of retinopathy can be detected. High glucose de-
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FIG. 3. PARP activity in the retina and covalent modiﬁcation of GAPDH. A: PARP activity was determined in the retinal extract by Western blot
technique. Poly(ADP-ribosyl)ated proteins were detected using antibody obtained from Santa Cruz Biotechnology. To determine covalent
modiﬁcation of GAPDH, it was immunoprecipitated from retinal proteins and analyzed by Western blot technique using monoclonal antibodies
against either PAR or nitrotyrosine. To ensure equal loading, the membranes were reprobed for GAPDH. The histograms represent ribosylation
(B) or nitration (C) of retinal GAPDH from ﬁve to six rats in each group, and the values from normal rat retina are considered to be 100%. *P <
0.05 compared with normal; #P > 0.05 compared with poor control.
FIG. 4. Effect of diabetes on subcellular localization of GAPDH.
Subcellular fractionation was performed on retinal homogenate by
centrifugation. GAPDH expression was determined by Western blot.
Histone 2B and LDH were used to determine the purity of nuclear and
cytosolic fractions, respectively. The histogram represents the relative
expression of GAPDH in cytosolic and nuclear fractions, and the total
expression of GAPDH in cytosol and nuclear fraction is considered to
be 100%. The values obtained are means  SD from four or more rats
in each of the four groups. *P < 0.05 compared with normal; #P > 0.05
compared with poor control.
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overproduction of superoxide by mitochondrial electron
transport chain (9). Retinal mitochondria are dysfunc-
tional in diabetes, and superoxide levels are elevated
(7,8,35); and complex III is considered one of the sources
of increased superoxide (8). Overexpression of MnSOD
that is shown to prevent glucose-induced inhibition of
GAPDH in vascular cells (9) also prevents the develop-
ment of retinopathy in diabetic mice (8). Thus, taken
together, data strongly implicate the role for GAPDH in the
pathogenesis of retinopathy in diabetes.
Mitochondrial superoxide break DNA strand and acti-
vate PARP, and PARP-mediated poly(ADP-ribosyl)ation of
GAPDH is considered one of the mechanisms in the
inhibition of GAPDH activity in hyperglycemic conditions
(14). Our data show that PARP activity is signiﬁcantly
increased in the poor-control group, and this is in accor-
dance with another published report (36). Increased PARP
activity plays an important role in diabetes-induced retinal
capillary cell death, and inhibitors of PARP prevent retinal
leukostasis, oxidative stress, and retinopathy in diabetic
rats (36–39). Here, we show that increased ribosylation of
retinal GAPDH could be one of the mechanisms responsi-
ble for its inactivation.
GAPDH is susceptible to nitration by peroxynitrite
(formed by reaction between nitric oxide and superoxide);
steady-state exposure of GAPDH to low doses of peroxyni-
trite in rat astrocytes results in its inhibition (15,16).
GAPDH is also a target for inactivation by nitric oxide in
endothelial cells (40), which are some of the microvascu-
lar cells in the retina that present pathology of diabetic
retinopathy. Nitric oxide and peroxynitrite levels are ele-
vated in the retina and its capillary cells, and these levels
remain elevated at duration when vascular histopathology
characteristic of retinopathy is developing in diabetic rats
(5,6,25,41–43). Our results clearly show that diabetes
increases nitration of retinal GAPDH, implying that nitra-
tion is associated with its inhibition. In support, covalent
modiﬁcation of GAPDH by nitration is also observed in
other pathological conditions associated with inﬂamma-
tion (44), and diabetic retinopathy is believed to be a
low-grade chronic inﬂammatory disease (45–48). Per-
oxynitrite itself damages DNA and triggers activation of
PARP (49); we clearly show that ribosylation of GAPDH is
also increased in diabetes. Furthermore, reduction in
retinal GAPDH expression (gene and protein) suggests
that, in addition to its covalent modiﬁcation, the gene
transcript of GAPDH is decreased in diabetes.
GAPDH is also a major intracellular messenger that
mediates cell death via apoptosis. Covalent modiﬁcation
of GAPDH is suggested to trigger its translocation from
cytosol to the nuclear fraction (12,13). During nuclear
translocation, its activity is lost (50), and an increase in
hydrophobicity due to its nitration is being postulated as
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FIG. 5. Glycolytic activity and covalent modiﬁcation of GAPDH in
cytosolic and nuclear fractions. A: The enzyme activity of GAPDH was
measured in the cytosolic and nuclear fractions of the retina by
measuring the increase in the production of NADH at 340 nm. Each
measurement was performed in duplicate, and assay was repeated
three or more times. The activity obtained in the cytosol obtained from
normal rat retina is considered to be 100%. The values are means  SD
from at least six rats in each of the four groups. *P < 0.05 compared
with normal; #P > 0.05 compared with poor control. B: Nitration of
GAPDH was performed by immunoprecipitating GAPDH from the
cytosolic and nuclear fractions of the retina, followed by separation on
SDS-Gel. The nitrated GAPDH was identiﬁed using antibody against
nitrotyrosine from Upstate Biotechnology. The blots are representa-
tive of four to ﬁve rats in each group.
FIG. 6. Activation of AGEs and PKC in retina. Total AGEs (A) and PKC
activation (B) were measured in the retinal homogenate by Western
blot technique using antibodies against anti-AGE and PKC II, respec-
tively. -Actin was used as a loading standard. These blots are repre-
sentative of four or more rats in each group.
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GAPDH is suggested to play a role in retinal glial cell
apoptosis in hyperglycemic conditions (13), and increased
apoptosis of retinal capillary cells precedes the develop-
ment of retinal pathology associated with diabetic retinop-
athy (32). Our results show that the expression of GAPDH
is increased in nuclear fraction in the retina from diabetic
rats compared with normal rats; however, the enzyme in
the nuclear fraction appears to be in a more nitrated and
inactivated state compared with the cytosol fraction. This
implies that although diabetes increases GAPDH translo-
cation to the nucleus, it is covalently modiﬁed before
being translocated from the cytosol and is in an inacti-
vated state.
Reinstitution of good control after 6 months of poor
control failed to produce any signiﬁcant beneﬁcial effects
on GAPDH, but if good control was initiated soon after
induction of diabetes in rats and allowed to continue for 12
months, GAPDH remained similar to that obtained from
age-matched normal rats. This strongly supports that in
addition to being a central player in the development of
diabetic retinopathy, GAPDH is important in the metabolic
memory phenomenon. Reversal of hyperglycemia failed to
provide any beneﬁt to the activation of PARP; the enzyme
remained activated even after 6 months of good con-
trol. Sustained increases in nitration and ribosylation of
retinal GAPDH after reversal of hyperglycemia in rats
suggests that good control fails to provide any beneﬁt to
the covalent modiﬁcations of the enzyme. Furthermore,
good control did not prevent translocation of the retinal
enzyme from cytosol to the nucleus, suggesting that
GAPDH remains proapoptotic even after good control is
reestablished. Because of tissue availability, apoptosis of
retinal capillary cells was not measured in this study;
however, in support of continued apoptosis, our previous
studies have shown that the apoptosis execution enzyme
caspase-3 remains active in the retina even after reversal
of hyperglycemia in rats. The process of caspase-3 activa-
tion that starts before the appearance of retinal histopa-
thology resists reversal by reinstitution of good control
(25), and nuclear accumulation of covalently modiﬁed
GAPDH could be one of the important factors associated
with increased apoptosis and histopathology of diabetic
retinopathy.
Inhibition of GAPDH increases the levels of glycolytic
metabolite glyceraldehyde 3- phosphate, and this activates
the major pathways implicated in diabetes complications,
including AGEs formation, PKC activation, and hex-
osamine pathway (10). Here, we show that the reversal of
hyperglycemia in rats, in addition to failing to provide
any beneﬁt to the inhibition of retinal GAPDH and its
nuclear translocation, has no signiﬁcant effect on GAPDH-
mediated pathways. Thus, both the downstream and up-
stream consequences of GAPDH inhibition persist for at
least 6 months after hyperglycemia is terminated, further
strengthening the role of GAPDH in the development/
progression of diabetic retinopathy.
Data presented here clearly show that the rats that
presented no effect of reversal of hyperglycemia on
GAPDH and its translocation to the nucleus also showed
no effect on the development of retinopathy; the number
of acellular capillaries remains comparable in the rats in
the poor-control and poor control–good control groups.
This conﬁrms that GAPDH-mediated pathways and the
process of apoptosis of retinal capillary cells that begins
before histopathology and can be detected in the retinal
vasculature (25) continue to progress even after hypergly-
cemia is terminated. The analyses of GAPDH, its translo-
cation and covalent modiﬁcation, and the consequences of
its inhibition on the pathways were performed in the
whole-retina samples, and this approach did not allow us
to identify the speciﬁc cell type. The failure to reverse the
development of retinal vascular histopathology by reinsti-
tution of good control, however, strongly suggests that
GAPDH has a signiﬁcant role in the development and
progression of diabetic retinopathy.
In conclusion, we have provided strong evidence dem-
onstrating that GAPDH is inhibited and its downstream
and upstream signaling pathway activated in the retina in
diabetes at a duration when histopathology characteristic
of retinopathy can be observed in rats. The covalent
modiﬁcation of the enzyme is increased. Diabetes acceler-
ated translocation of retinal GAPDH into the nucleus,
suggesting that its proapoptotic nature possibly contrib-
utes to the development of diabetic retinopathy. In addi-
tion to its role in the pathogenesis of diabetic retinopathy,
GAPDH is also important in the metabolic memory phe-
nomenon. Sustained nitration and ribosylation are possi-
FIG. 7. Histopathology in retinal microvasculature of normal rats (left panel) and those in a state of poor control (right panel). Trypsin-digested
retinal microvasculature was stained with periodic acid Schiff and hematoxylin. The number of acellular capillaries was counted in multiple
midretinal ﬁelds and standardized to retinal area (per square millimeter). The arrows indicate acellular capillaries in the trypsin-digested
microvessels obtained from a rat that was maintained in poor control for 12 months. (Please see http://dx.doi.org/10.2337/db08-1025 for a
high-quality digital representation of this ﬁgure.)
GADPH AND DIABETIC RETINOPATHY
232 DIABETES, VOL. 58, JANUARY 2009ble mechanisms for resistance of GAPDH to reverse
inhibition after reversal of hyperglycemia. Therapies tar-
geted toward preventing GAPDH inhibition by blocking its
covalent modiﬁcation should help in the development and
also in arresting the progression of diabetic retinopathy, a
sight-threatening complication of diabetes.
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